Patients in cell therapy Carvykti trial in remission after 5 years
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
Myeloma
Turning our darkness into someone else’s light
When I recently read that former U.S. President Joe Biden had been diagnosed with prostate cancer and it had spread to his bones, my heart…
EU committee recommends Blenrep combos for approval in RRMM
A committee of the European Medicines Agency has recommended approving GSK’s Blenrep (belantamab mafodotin) in combination with other therapeutic agents to treat relapsed or refractory…
How I’m dealing with caregiver guilt while caring for my mum
I wanted to scream at my mother last Tuesday when she insisted on skipping her medication because she didn’t feel like taking it. While she…
FDA committee votes in favor of Darzalex Faspro for HR-SMM
A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…
The unspoken weight of becoming a caregiver
I’ll never forget the day that my mother was diagnosed with myeloma. That was when the word “son” was entirely erased from my identity.
Cell therapy anito-cel extends treatment-resistant RRMM survival
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
IGI’s relapsed/refractory multiple myeloma drug wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…
Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM
The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
Trial data for 2 Caribou CAR T-cell therapies due this year
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
